Mycophenolate mofetil in neuropsychiatric systemic lupus erythematosus.

Abstract

Neuropsychiatric abnormalities frequently occur in patients with systemic lupus erythematosus, affecting as many as 14-75% of people with this disease. High-dose steroid with or without anticoagulation is the mainstay of treatment in neuropsychiatric systemic lupus erythematosus (NPSLE). Use of mycophenolate as a steroid sparing drug may be a potential alternative agent in the therapy of NPLE, but lack of randomized trials and cost prohibit its widespread use. Its safety profile is higher than that of cyclophosphamide and azathioprine. We report a successfully treated case of neuropsychiatric systemic lupus erythematosus, presenting as psychosis, whose long-term remission was maintained on treatment with mycophenolate mofetil.

• Authors: J Jose, B K Paulose, Z Vasuki, D Danda
• Journal: Indian journal of medical sciences (Indian J Med Sci) Vol. 59 Issue 8 Pg. 353-6 (Aug 2005) ISSN: 0019-5359 [Print] India
• PMID: 16129929 (Publication Type: Case Reports, Journal Article)

Chemical References

• Immunosuppressive Agents
• Mycophenolic Acid

Topics

• Adult
• Female
• Humans
• Immunosuppressive Agents (therapeutic use)
• Lupus Vasculitis, Central Nervous System (drug therapy)
• Mycophenolic Acid (analogs & derivatives, therapeutic use)